Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy
Jacqueline V. Aredo, Isa Mambetsariev, Jessica A. Hellyer, Arya Amini, Joel W. Neal, Sukhmani K. Padda, Caroline E. McCoach, Jonathan W. Riess, Elwyn C. Cabebe, Jarushka Naidoo, Tariq Abuali, Ravi Salgia, Billy W. Loo, Maximilian Diehn, Summer S. Han, Heather A. Wakelee
Topics & Concepts
DurvalumabMedicinePneumonitisOsimertinibChemoradiotherapyInternal medicineAdverse effectOncologyCancerNivolumabImmunotherapyEpidermal growth factor receptorLungErlotinibCancer Immunotherapy and BiomarkersLung Cancer Treatments and MutationsColorectal Cancer Treatments and Studies